person · Reporting owner

Rosenberg David I.

Disclosed activity across 2 companies

Tapewire entity: 64507
SEC CIK: 0001842508

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Illumination Acquisition Corp. IILLU · Entity 5913	Director · Chairman · 10% owner	February 26, 2026	February 26, 2026
Peak Bio, Inc.PKBO · Entity 85431	Director	November 01, 2022	November 03, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Illumination Acquisition Corp. I

Report date February 26, 2026 · Filed February 26, 2026

Jointly reported with Illumination Acquisition 1 Sponsor LLC, LIPMAN JOHN C

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	IndirectBy Illumination Acquisition 1 Sponsor LLC	365,000	Reported balance Holding disclosure · report date 2026-02-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 365,000 F1: Represents 365,000 Class A ordinary shares contained within units that the reporting person has irrevocably agreed to purchase at the closing of the Issuer's initial public offering (the "IPO"). Does not include up to an additional 30,000 Class A ordinary shares contained within units that the reporting person has irrevocably agreed to purchase in connection with the IPO if and only if the underwriters of the IPO fully exercise their over-allotment option. F2: Represents securities held by Illumination Acquisition 1 Sponsor LLC. John Lipman and David I. Rosenberg indirectly control the management of such entity, including the exercise of voting and investment discretion with respect to the securities held of record by such entity.
Class B Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy Illumination Acquisition 1 Sponsor LLC	Not disclosed	Reported balance Holding disclosure · report date 2026-02-26 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: The Class B ordinary shares of the Issuer are convertible into the Issuer's Class A ordinary shares concurrently with or immediately following the consummation of an initial business combination, or earlier at the option of the holders thereof on a one-for-one basis, subject to the adjustments. The Class B ordinary shares have no expiration date. F4: Includes up to 1,000,000 Class A ordinary shares issuable upon conversion of Class B ordinary shares that are subject to forfeiture in the event the underwriters of the Issuer's IPO do not exercise their over-allotment option in full. F2: Represents securities held by Illumination Acquisition 1 Sponsor LLC. John Lipman and David I. Rosenberg indirectly control the management of such entity, including the exercise of voting and investment discretion with respect to the securities held of record by such entity.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50	IndirectBy Illumination Acquisition 1 Sponsor LLC	Not disclosed	Reported balance Holding disclosure · report date 2026-02-26 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F5: Represents warrants contained within units that the reporting person has irrevocably agreed to purchase at the closing of the Issuer's IPO. F6: Each warrant will become exercisable at the later of 12 months from the closing of the IPO and 30 days after the completion of the Issuer's initial business combination. F7: Each warrant will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or the Issuer's liquidation. F8: Does not include up to an additional 10,000 Class A ordinary shares underlying warrants contained within units that the reporting person has irrevocably agreed to purchase in connection with the IPO if and only if the underwriters of the IPO fully exercise their over-allotment option. F2: Represents securities held by Illumination Acquisition 1 Sponsor LLC. John Lipman and David I. Rosenberg indirectly control the management of such entity, including the exercise of voting and investment discretion with respect to the securities held of record by such entity.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 365,000 Class A ordinary shares contained within units that the reporting person has irrevocably agreed to purchase at the closing of the Issuer's initial public offering (the "IPO"). Does not include up to an additional 30,000 Class A ordinary shares contained within units that the reporting person has irrevocably agreed to purchase in connection with the IPO if and only if the underwriters of the IPO fully exercise their over-allotment option.

F2: Represents securities held by Illumination Acquisition 1 Sponsor LLC. John Lipman and David I. Rosenberg indirectly control the management of such entity, including the exercise of voting and investment discretion with respect to the securities held of record by such entity.

F3: The Class B ordinary shares of the Issuer are convertible into the Issuer's Class A ordinary shares concurrently with or immediately following the consummation of an initial business combination, or earlier at the option of the holders thereof on a one-for-one basis, subject to the adjustments. The Class B ordinary shares have no expiration date.

F4: Includes up to 1,000,000 Class A ordinary shares issuable upon conversion of Class B ordinary shares that are subject to forfeiture in the event the underwriters of the Issuer's IPO do not exercise their over-allotment option in full.

F5: Represents warrants contained within units that the reporting person has irrevocably agreed to purchase at the closing of the Issuer's IPO.

F6: Each warrant will become exercisable at the later of 12 months from the closing of the IPO and 30 days after the completion of the Issuer's initial business combination.

F7: Each warrant will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or the Issuer's liquidation.

F8: Does not include up to an additional 10,000 Class A ordinary shares underlying warrants contained within units that the reporting person has irrevocably agreed to purchase in connection with the IPO if and only if the underwriters of the IPO fully exercise their over-allotment option.

Peak Bio, Inc.

Report date November 01, 2022 · Filed November 03, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,514,700	Last balance in matching sequence After 2022-11-01 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2022-11-01 · Exercise / conversion · Acquired 1,437,500 · Balance 1,437,500 F2: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein. Row 2 · 2022-11-01 · Other · Acquired 77,200 · Balance 1,514,700 F4: Pursuant to a Payment Agreement between Ignyte and the Sposnor entered into connection with the Business Combination, the Sponsor received these securities in a private placement in lieu of the aggregate principal amount of working capital loans owed to the Sponsor by Ignyte. F2: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein.
Class F Common StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2022-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-01 · Conversion · Disposed 1,437,500 · Balance 0 F1: On November 1, 2022, Ignyte Acquisition Corp. ("Ignyte" and the former name of the Issuer) consummated its initial business combination (the "Business Combination") with Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea. In connection with the consummation of the Business Combination, each share of Class F common stock, par value $0.0001 per share, of Ignyte automatically converted into one share of Class A common stock, par value $0.0001 per share, of the Issuer. F2: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein.
Private Placement WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-11-01	IndirectSee Footnote	2,500,000	Reported balance After 2022-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-01 · Grant · Acquired 2,500,000 · Balance 2,500,000 F3: The private placement warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934 concurrent with the closing of the Business Combination (the "Closing"), because, pursuant to their terms, their exercise was not within the control of the Reporting Person until the Closing. Each private placement warrant is exercisable for one share of the Issuer's Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants may be exercised commencing 30 days after the Closing and expire five years after the Closing or earlier upon redemption or liquidation. The private placement warrants consist of 2,500,000 private placement warrants purchased by the Sponsor in a private placement from Ignyte simultaneously with the consummation of Ignyte's initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: On November 1, 2022, Ignyte Acquisition Corp. ("Ignyte" and the former name of the Issuer) consummated its initial business combination (the "Business Combination") with Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea. In connection with the consummation of the Business Combination, each share of Class F common stock, par value $0.0001 per share, of Ignyte automatically converted into one share of Class A common stock, par value $0.0001 per share, of the Issuer.

F2: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein.

F3: The private placement warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934 concurrent with the closing of the Business Combination (the "Closing"), because, pursuant to their terms, their exercise was not within the control of the Reporting Person until the Closing. Each private placement warrant is exercisable for one share of the Issuer's Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants may be exercised commencing 30 days after the Closing and expire five years after the Closing or earlier upon redemption or liquidation. The private placement warrants consist of 2,500,000 private placement warrants purchased by the Sponsor in a private placement from Ignyte simultaneously with the consummation of Ignyte's initial public offering.

F4: Pursuant to a Payment Agreement between Ignyte and the Sposnor entered into connection with the Business Combination, the Sponsor received these securities in a private placement in lieu of the aggregate principal amount of working capital loans owed to the Sponsor by Ignyte.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 01, 2022 Filed Nov 3, 2022 21:52 UTC	Peak Bio, Inc. PKBO · Entity 85431	GrantPrivate Placement Warrants · Derivative	2,500,000	$1.00 Strike: $11.50	$2,500,000.00	Disclosure SEC source: 0000899243-22-035083 · doc4.xml · derivative · entry 4 Rosenberg David I. · CIK 0001842508 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2027-11-01 F3 · kind: The private placement warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934 concurrent with the closing of the Business Combination (the "Closing"), because, pursuant to their terms, their exercise was not within the control of the Reporting Person until the Closing. Each private placement warrant is exercisable for one share of the Issuer's Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants may be exercised commencing 30 days after the Closing and expire five years after the Closing or earlier upon redemption or liquidation. The private placement warrants consist of 2,500,000 private placement warrants purchased by the Sponsor in a private placement from Ignyte simultaneously with the consummation of Ignyte's initial public offering. F3 · ownership.nature: The private placement warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934 concurrent with the closing of the Business Combination (the "Closing"), because, pursuant to their terms, their exercise was not within the control of the Reporting Person until the Closing. Each private placement warrant is exercisable for one share of the Issuer's Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants may be exercised commencing 30 days after the Closing and expire five years after the Closing or earlier upon redemption or liquidation. The private placement warrants consist of 2,500,000 private placement warrants purchased by the Sponsor in a private placement from Ignyte simultaneously with the consummation of Ignyte's initial public offering. Read SEC document
November 01, 2022 Filed Nov 3, 2022 21:52 UTC	Peak Bio, Inc. PKBO · Entity 85431	ConversionClass F Common Stock · Derivative	1,437,500	$0.00	$0.00	Disclosure SEC source: 0000899243-22-035083 · doc4.xml · derivative · entry 3 Rosenberg David I. · CIK 0001842508 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,437,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 1, 2022, Ignyte Acquisition Corp. ("Ignyte" and the former name of the Issuer) consummated its initial business combination (the "Business Combination") with Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea. In connection with the consummation of the Business Combination, each share of Class F common stock, par value $0.0001 per share, of Ignyte automatically converted into one share of Class A common stock, par value $0.0001 per share, of the Issuer. F1 · derivative.exercise_date: On November 1, 2022, Ignyte Acquisition Corp. ("Ignyte" and the former name of the Issuer) consummated its initial business combination (the "Business Combination") with Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea. In connection with the consummation of the Business Combination, each share of Class F common stock, par value $0.0001 per share, of Ignyte automatically converted into one share of Class A common stock, par value $0.0001 per share, of the Issuer. F1 · derivative.expiration_date: On November 1, 2022, Ignyte Acquisition Corp. ("Ignyte" and the former name of the Issuer) consummated its initial business combination (the "Business Combination") with Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea. In connection with the consummation of the Business Combination, each share of Class F common stock, par value $0.0001 per share, of Ignyte automatically converted into one share of Class A common stock, par value $0.0001 per share, of the Issuer. F2 · ownership.nature: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 3, 2022 21:52 UTC	Peak Bio, Inc. PKBO · Entity 85431	OtherCommon Stock	77,200	$0.00	$0.00	Disclosure SEC source: 0000899243-22-035083 · doc4.xml · nonDerivative · entry 2 Rosenberg David I. · CIK 0001842508 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,514,700 F4 · price: Pursuant to a Payment Agreement between Ignyte and the Sposnor entered into connection with the Business Combination, the Sponsor received these securities in a private placement in lieu of the aggregate principal amount of working capital loans owed to the Sponsor by Ignyte. F2 · ownership.nature: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein. Read SEC document
November 01, 2022 Filed Nov 3, 2022 21:52 UTC	Peak Bio, Inc. PKBO · Entity 85431	Exercise / conversionCommon Stock	1,437,500	$0.00	$0.00	Disclosure SEC source: 0000899243-22-035083 · doc4.xml · nonDerivative · entry 1 Rosenberg David I. · CIK 0001842508 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,437,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: These securities are held by Ignyte Sponsor LLC (the "Sponsor"). The Reporting Person is a managing member of the Sponsor and shares voting and dispositive power of the securities held by the Sponsor. Accordingly, the Reporting Person may be deemed to have or share beneficial ownership of such securities. The Reporting Person disclaim beneficial ownership of the securities held by the Sponsor, except to the extent of any pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.